Acivir Pills: Effective Antiviral Relief for Herpes Infections
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.86 | $51.36 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $77.04 $65.46 (15%) | 🛒 Add to cart |
| 120 | $0.68 | $102.71 $81.57 (21%) | 🛒 Add to cart |
| 180 | $0.62 | $154.07 $111.78 (27%) | 🛒 Add to cart |
| 270 | $0.58 | $231.11 $156.09 (32%) | 🛒 Add to cart |
| 360 | $0.56
Best per pill | $308.14 $201.40 (35%) | 🛒 Add to cart |
Acivir Pills contain the active ingredient acyclovir, a nucleoside analogue DNA polymerase inhibitor specifically designed to combat herpesvirus infections. This oral formulation is a cornerstone in the management of both initial and recurrent episodes of herpes simplex and herpes zoster, offering a targeted mechanism to suppress viral replication. By interfering with viral DNA synthesis, Acivir reduces the duration and severity of outbreaks, accelerates healing, and can be used prophylactically to prevent recurrences in immunocompetent and immunocompromised patients. Its well-established pharmacokinetic profile ensures systemic distribution to infected cells, making it a first-line therapeutic option recommended by dermatological and infectious disease guidelines worldwide.
Features
- Active ingredient: Acyclovir 200mg, 400mg, or 800mg film-coated tablets
- Mechanism: Selective inhibition of viral DNA polymerase via competitive incorporation as a guanosine analogue
- Bioavailability: Approximately 15-30%, with dose-proportional increases in plasma concentration
- Half-life: 2.5-3.3 hours in adults with normal renal function
- Excretion: Primarily renal via glomerular filtration and tubular secretion
- Packaging: Blister packs of 10, 30, or 60 tablets with tamper-evident seals
Benefits
- Significantly reduces healing time for herpes lesions by inhibiting viral replication at the cellular level
- Decreases the duration of viral shedding, lowering transmission risk to susceptible individuals
- Alleviates associated symptoms such as pain, burning, and itching through rapid antiviral action
- Can reduce the frequency and severity of recurrent outbreaks when used as chronic suppressive therapy
- Well-tolerated profile with extensive clinical documentation supporting efficacy and safety
- Available in multiple strengths allowing for flexible dosing regimens tailored to infection type and patient status
Common use
Acivir Pills are indicated for the treatment of herpes simplex virus (HSV) infections, including initial and recurrent genital herpes, and herpes labialis (cold sores). They are also approved for the treatment of acute herpes zoster (shingles) and for the suppression of recurrent genital herpes in immunocompetent and immunocompromised patients. Off-label uses may include prophylaxis in HSV-seropositive patients undergoing immunosuppressive therapy and management of herpes whitlow. Clinical decision-making should be based on virological confirmation where possible, though empirical treatment is often initiated based on characteristic presentation.
Dosage and direction
Dosage must be individualized based on infection type, renal function, and immunologic status. For genital herpes: 200mg five times daily for 10 days (initial episode) or 400mg three times daily for 5 days (recurrent episodes). For chronic suppression: 400mg twice daily. Herpes zoster: 800mg five times daily for 7-10 days. Tablets should be swallowed whole with water, with or without food, though administration with food may minimize gastrointestinal discomfort. Dosage adjustment is mandatory in patients with renal impairment (CrCl <50 mL/min). Treatment should be initiated at the earliest sign or symptom of recurrence for maximum efficacy.
Precautions
Maintain adequate hydration to prevent crystalluria, particularly in elderly patients or those with pre-existing renal conditions. Use with caution in patients with neurological abnormalities, severe hepatic impairment, or electrolyte imbalances. Monitor renal function during treatment, especially with concomitant nephrotoxic drugs. Pregnancy Category B: use only if potential benefit justifies potential risk. Breastfeeding considerations: acyclovir concentrates in milk; weigh infant risk versus maternal benefit. Pediatric use is approved for chickenpox (from 2 years) and must be weight-based. Geriatric patients often require dose adjustment due to reduced renal clearance.
Contraindications
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Absolute contraindication in patients with history of severe neurological reactions to previous antiviral therapy. Not recommended in patients with CrCl <10 mL/min without dialysis adjustments. Avoid use in patients with rare genetic disorders of purine metabolism. Concomitant use with other nephrotoxic agents may represent a relative contraindication depending on clinical context.
Possible side effect
Common (>1%): nausea, vomiting, diarrhea, headache. Less common: dizziness, fatigue, skin rash, pruritus. Rare but serious: acute renal failure, crystalluria, neurological symptoms (agitation, confusion, tremor, hallucinations), hepatotoxicity, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). Most adverse reactions are dose-related and reversible upon discontinuation. Patients should report any signs of hypersensitivity reaction (urticaria, angioedema) or neurological changes immediately.
Drug interaction
Probenecid significantly reduces acyclovir renal clearance, increasing AUC and half-life—monitor for toxicity. Concurrent use with other nephrotoxic agents (aminoglycosides, cyclosporine, NSAIDs) may increase risk of renal dysfunction. Potential additive effects with other neurotoxic drugs. No clinically significant interactions with cytochrome P450 system. Zidovudine may potentiate fatigue and lethargy.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for the missed one. Maintaining consistent dosing intervals is critical for effective viral suppression, particularly during acute treatment phases. For chronic suppression, occasional missed doses are unlikely to significantly impact efficacy, but habitual non-adherence may increase recurrence risk.
Overdose
Symptoms may include agitation, coma, lethargy, seizures, and renal impairment. Management is supportive: maintain adequate hydration to promote renal excretion. Hemodialysis significantly enhances acyclovir removal (approximately 60% reduction in plasma levels per 4-hour session). Contact poison control center immediately for specific management guidance. There is no specific antidote.
Storage
Store at controlled room temperature (15-30°C) in original packaging, protected from light and moisture. Keep blister strips sealed until use. Do not transfer to alternative containers. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any tablets showing signs of physical degradation.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing existing therapy. Individual response to treatment may vary based on clinical status, comorbidities, and adherence. The manufacturer is not liable for misuse or incorrect interpretation of this data.
Reviews
Clinical studies demonstrate 70-80% reduction in healing time for primary genital herpes and 50% reduction in recurrence frequency with suppressive therapy. Patient-reported outcomes indicate high satisfaction with symptom control and convenience of oral dosing. Some reports note gastrointestinal discomfort as a limiting factor, though generally manageable with food co-administration. Long-term safety data support use for suppression up to 10 years. Real-world evidence confirms alignment with clinical trial results regarding efficacy and tolerability profiles.